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Combination therapy of bortezomib with other chemotherapeutics is an emerging treatment strategy. Since both curcumin and
bortezomib inhibit NF-𝜅B, we tested the effects of their combination on leukemia cells. To improve potency, a novel Mannich-
type curcumin derivative, C-150, was synthesized. Curcumin and its analogue showed potent antiproliferative and apoptotic
effects on the human leukemia cell line, HL60, with different potency but similar additive properties with bortezomib. Additive
antiproliferative effects were correlated well with LPS-induced NF-𝜅B inhibition results. Gene expression data on cell cycle and
apoptosis related genes, obtained by high-throughput QPCR, showed that curcumin and its analogue act through similar signaling
pathways. In correlation with in vitro results similar additive effect could be obsereved in SCID mice inoculated systemically with
HL60 cells. C-150 in a liposomal formulation given intravenously in combination with bortezomib was more efficient than either
of the drugs alone. As our novel curcumin analogue exerted anticancer effects in leukemic cells at submicromolar concentration
in vitro and at 3mg/kg dose in vivo, which was potentiated by bortezomib, it holds a great promise as a future therapeutic agent in
the treatment of leukemia alone or in combination.
1. Introduction
Curcumin, also known as diferuloyl methane, a natural
component of the rhizome of Curcuma longa has emerged
as one of the most powerful chemopreventive and anticancer
agents. It has been reported to exert anti-inflammatory,
antiangiogenic, and antiproliferative activity in various types
of cancer [1–3]. It has also been shown that curcumin
elevates intracellular ROS and induces loss of mitochondrial
membrane potential and apoptosis in leukemia cells [4, 5].
In concert with these observations, the potent antileukemic
action of curcumin and some of its derivatives have been
reviewed recently [6]. This natural compound not only can
be used as chemotherapeutics but also was suggested for
chemoprevention [6].
A variety of molecular mechanisms have been proposed
to mediate anticancer effects of curcumin, but its ability
to inhibit the growth of various types of cancer cells at
various stages of cancer progression is probably due to its
potential to act on multiple targets [7–9]. Among others,
it acts as a scavenger of free radicals [10], inhibits NF-𝜅B
activation [11], and modulates histone deacetylase (HDAC)
and histone acetyltransferase (HAT) enzyme activities [12,
13] and DNA methyltransferase 1 [10]. The main underlying
action mechanisms of curcumin are probably based on the
modulation ofmultiple important cellular signaling pathways
includingNF-𝜅B, TRAIL, PI3K/Akt, JAK/STAT,Notch-1, and
JNK [5, 14].
Several preclinical and clinical studies suggest that cur-
cumin may represent a novel strategy to treat cancer patients
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alone or in combination with already existing therapeutic
regimens [2, 15]. However, the in vivo application of cur-
cumin has been limited for its low potency and unsatisfactory
bioavailability [16], which necessitates the application of new
formulation solutions and the synthesis of novel curcumin
analogues with improved pharmacological properties, while
retaining a similar safety profile.
Different synthetic concepts have been therefore devel-
oped to expand the molecular diversity, from the side-
chain and diketone transformations to alkyl and alkenyl
functionalizations on C-4 in the central position or with
different substituents at the 4 positions of the phenyl group
of curcumin [17–20]. Here, we report the application of a
novel Mannich-type curcumin derivative, C-150, possessing
metahydroxyphenyl side-chains and 3-phenyl-3-acrylamido
branched central motif. The new analogue is one of the most
potent members of the synthesized analogues [21].
Previous reports demonstrated that bortezomib (Vel-
cade, formerly known as PS-341), a potent and selective
proteasome inhibitor approved by the FDA for the treat-
ment of patients with multiple myeloma, is able to block
chemotherapy-induced NF-𝜅B activation and augment the
apoptotic response to chemotherapeutic agents [22].
NF-𝜅B signaling plays a critical role in cancer devel-
opment and progression; constitutive activation of NF-𝜅B
pathway has been reported in different types of cancer,
including multiple myeloma and acute myeloid leukemias
[23, 24]. After stimulation and activation of the canonical
NF-𝜅B pathway in noncancer cells, I𝜅B is phosphorylated
by IKK then degradated by the 26S proteasome allowing
the nuclear transport of NF-𝜅B. Since I𝜅B is a substrate of
the proteasome, the initial rationale for use of bortezomib
in multiple myeloma was inhibition of NF-𝜅B activity and
inhibition of cell proliferation and survival [25, 26].
Beside the canonical pathway, several studies show a
critical role for the noncanonical NF-𝜅B pathway in cancer
pathogenesis as well. Hideshima et al. found that bortezomib
could inhibit the noncanonical pathway via inhibition of
conversion of p100 to p52 and its nuclear translocation in
multiple myeloma cells [27].
It has been shown that bortezomib possesses in vitro and
in vivo activity against a variety of malignancies, including
acute and chronic lymphocytic leukemia, prostate cancer,
pancreatic cancer, and colon cancer [22]. Combination ther-
apy of bortezomibwith other chemotherapeutical agents is an
emerging treatment strategy not only in myeloma but also in
leukemia [28]. Since both curcumin and bortezomib inhibit
NF-𝜅B, we hypothesized their additive anticancer effects on
leukemia cells.
Several studies reported enhanced cytotoxicity of borte-
zomib in multiple myeloma cells when combined with
curcumin or its analogues both in vitro and in vivo [28–
31]. In multiple myeloma cells, the combined treatment
inactivated NF-𝜅B while it activated JNK signaling [31], but
no information has been available on leukemia cells.
In this report, we studied curcumin and a novelMannich-
type curcumin analogue C-150 alone and in combination
with bortezomib. Effects of cotreatment were studied on
cytotoxicity, NF-𝜅B inhibition, gene expression, and in an in
vivo mouse model.
2. Materials and Methods
2.1. Cell Culturing. Human leukemia cells (HL60) were
obtained from ATCC, USA. Cells were cultured at 37∘C
under 5% CO
2
and 100% humidity in LeviTubes designed
for use in the bench top bioreactor-incubator hybrid BioLe-
vitator (Hamilton, Hungary). During cultivation, cells were
proliferated in suspension with rotation without the use of
microcarriers. Rotation period was 2 seconds with 1 second
pause at 65 rpm. LeviTubes were filled with 40mL RPMI
cell culture medium containing 10% fetal bovine serum,
1x GlutaMAX, and penicillin-streptomycin antibiotics (Life
Technologies, Hungary). Culture medium was changed after
48 hours by removing half of the volume of the culture
medium and replacing it with fresh medium.
2.2. Cell Viability Measurements. Viability of HL60 human
leukemia cells was determined by the colorimetric MTS
assay (CellTiter 96 AQueous Assay, Promega, Madison, WI)
and by the CellTiter-Glo luminescent cell viability assay
(Promega, Madison, WI). The cells were seeded into 96-well
plates at 7000 cells/well density and cultured overnight before
treatment. Effects of curcumin (5, 10, 25, and 50 𝜇M), C-150
(50, 100, and 500 nM and 1 𝜇M), bortezomib (0.78, 3.125,
12.5, and 50 nM), and their combinations were recorded 48
hours after treatment. MTS reagent (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-
tetrazo-lium) or CellTiter-Glo reagent was applied to drug
treated and control (0.2% DMSO) cells according to the
manufacturer’s protocol. Absorbance (at 490 nm) and lumi-
nescence were recorded on a multimode microplate reader
(Victor, Perkin Elmer).
Viability was calculated with relation to untreated control
cells from three parallel measurements for all conditions. For
statistical significance, two-tailed Student’s 𝑡-test was used.
2.3. Measurements of NF-𝜅B Inhibition. Mouse B16 melan-
oma cell line was obtained from ATCC, USA. Cells were
cultured in RPMImedium (Life Technologies, Hungary) sup-
plemented with 10% FCS (Life Technologies, Hungary). NF-
𝜅B reporter cell lines were created by transfection with the
pNF-𝜅B-Luc/neo reporter construct with the Lipofectamine
2000 reagent (Invitrogen) and stable cell lines were selected
by G418 (Sigma) treatment.
B16/NF-𝜅B-Luc cells (6 × 104 cells/well) were grown
on luminoplates (Corning Life Sciences, Kentucky, USA)
overnight under standard cell culturing conditions. Before
treatment with curcumin (5, 10, 25, and 50 𝜇M), C-150 (50,
100, and 500 nM and 1 𝜇M), bortezomib (0.78, 3.125, 12.5,
and 50 nM) and their combinations, the NF-𝜅B-Luc reporter
gene was induced by adding LPS (500 ng/mL) into the cell
culture media (500 ng/mL). After 6 hours of incubation with
curcumin, C-150, bortezomib, or their combinations, the
mediumwas removed; cells were washed and lysed for 10min
at room temperature in cell culture lysis reagent (20 𝜇L/well;
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Promega). Substrate was added (20 𝜇L/well; Promega), and
luciferase activity was measured in a microplate reader
(Victor, Perkin Elmer). NF-𝜅B inhibition was calculated
with relation to untreated control cells from three parallel
measurements for all conditions.
2.4. FACS Analysis. HL60 cells (105) were plated in 24-
well tissue culture plates (Corning Life Sciences). Cells were
treated with curcumin (25 𝜇M), C-150 (300 and 600 nM),
bortezomib (20 nM), and their combinations in triplicates.
After 48 hours, cells were collected and resuspended in
annexin V binding buffer (0.01M HEPES, 0.14M NaCl,
and 2.5mM CaCl
2
). Annexin V-Alexa 488 (Life Technolo-
gies, 2.5 : 100) and propidium iodide (PI) (Sigma-Aldrich,
10 𝜇g/mL) were added to the cells and placed for 15min
in dark at room temperature. After washing, the cells were
analyzed on the FACSCalibur cytofluorimeter (Becton Dick-
inson). Percentage of FL1 (annexin V-Alexa 488) positive and
FL3 (propidium iodide) negative early apoptotic cells and FL1
(annexin V-Alexa 488) positive and FL3 (propidium iodide)
positive late apoptotic cells was determined. For statistical
significance, two-tailed Student’s 𝑡-test was used.
2.5. Gene Expression Analysis by High-Throughput QPCR.
HL60 leukemia cells (106) were plated on 10 cm2 tissue culture
plates (Corning Life Sciences). Cells were treated with cur-
cumin, C-150, bortezomib, and their combinations. 48 h after
treatment, cells were collected and centrifuged (3000 rpm,
5min) and total RNA was purified from treated and control
(0.2% DMSO) cells using AccuPrep Viral RNA Extraction
kit (Bioneer Corp., Korea) with a modified protocol as
described earlier [32]. Briefly, cells were lysed with RA1 lysis
buffer (Macherey-Nagel, Du¨ren, Germany) and applied to the
Viral RNA Extraction binding tube and then washed and
eluted with the protocol recommended by the manufacturer.
The quantity of total RNA was measured by NanoDrop
1000 spectrophotometer. 6𝜇g total RNA was converted into
cDNA with the High-Capacity cDNA Archive Kit (Applied
Biosystems, Foster City, CA) in a total volume of 60𝜇L.
Identical reaction volumes were prepared by the Agilent
Bravo Liquid handling Platform (Agilent Technologies) in
a 16 × 96-well design according to Agilent and Roche’s
recommendations. Each 2𝜇L reaction mixture contained
6 ng cDNA, 10 pmole gene specific primers, and 1𝜇L 2x Light-
Cycler1536 Probes Master (Roche). The following amplifi-
cation protocol was used: 95∘C for 1 minute (activation),
60 cycles of 95∘C for 10 seconds, and 60∘C for 10 seconds,
followed by 40∘C for 10 second final cooling. Amplification
was performed on the LightCycler 1536 System (Roche
Applied Science) using the real-time ready human cell cycle
regulation panel and the real-time ready human apoptosis
panel (Roche Applied Science). Each panel consists of 84 cell
cycles and apoptosis related assays along with seven human
reference genes (ACTB, 𝛽2M, GAPDH,HPRT1, RPL13A, 18S,
and YWHAZ).
Data was collected and processed using the LightCycler
1536 SW 1.0 software. Curves were analyzed by using dynamic
tube and slope correction methods. Relative expression of
the analyzed genes was normalized to the mean value of the
reference genes.
2.6. Liposome Formulation of C-150. Liquid phase C-150
containing liposomes was produced by dissolving lipid pow-
der of CHOL/PC/DSPE-mPEG (62/28/0.6mol%) and C-
150 (9.2mol%) in ethanol. The solution was transferred to
a rotary evaporator and dried overnight in vacuum. The
lipid film was hydrated and redispersed in PBS solution to
a final C-150 concentration of 0.5mM for 25min over the
phase transition temperature of the organic components.The
dispersion was subjected to size extrusion (0.45 𝜇mpore size)
and finally filtered through sterile filters (0.22𝜇m pore size).
After preparation, droplet size and polydispersity index of the
liposomes were determined. The droplet size, SSA, and PDI
of liposomes were measured by laser diffractometry (𝑛 = 5)
by the wet method.The d0.1, d0.5 as median and d0.9 droplet
size values, SSA, and PDI values were 75±19 nm, 114±20 nm,
178 ± 24 nm, 54.5m2/g, and 0.901 ± 0.20, respectively.
2.7. In Vivo Effects of C-150 and Bortezomib in a Xenograft
Model. 8-week-old male NOD CB17-Prkdcscid/NcrCrl mice
(Charles River, InnovoKft., Hungary) were used.The animals
were kept in individual ventilated cages to avoid any infec-
tion. All mice were fed a commercial sterile diet and water
ad libitum and were housed in an animal facility under a 12 h
light/dark cycle at constant temperature and humidity.
For the induction of rodentmodel of human leukemia 106
HL60, human leukemia cells were injected in 100𝜇L volume
intravenously. 3 days after cancer cell inoculation mice were
randomized and treated 5 times a week for 2 weeks.
Four different groups, each containing 8 mice, were stud-
ied: PBS control, bortezomib (0.15mg/kg), C-150 (3mg/kg),
and C-150 (3mg/kg) + bortezomib (0.15mg/kg). All animals
were treated moribund and were euthanized at the observa-
tion of the first sign of torment. The study was performed
according to the Institutional and National Animal Experi-
mentation and Ethics Guidelines in possession of an ethical
clearance (XXIX./3610/2012).
2.8. Statistical Analysis. All data presented are means ±
standard deviation (SD) as indicated in the text.The statistical
comparisons were performed by two-tailed Student’s 𝑡-test
using Microsoft Excel. In all statistical comparisons, a proba-
bility (𝑃) value of less than 0.05 was considered significant.
3. Results and Discussion
3.1. In Vitro Effect of Curcumin and Its Analogue Alone
and in Combination with Bortezomib. We have utilised two
common viability assays to assess the cytotoxic effects of
curcumin and the novel analogue C-150 on HL60 cells.
Combinations of curcumin or C-150 with bortezomib were
also investigated. The colorimetric MTS assay and the lumi-
nescence based CellTiter-Glo (CTG) assay yielded compa-
rable results; however, additive effects could be registered
at different concentrations (Tables 1 and 2). We found that
the CellTiter-Glo assay resulted in additive effects at lower
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Table 1: Cell viability measurements (MTS) of curcumin (C), C-150, and bortezomib (BTZ) alone and combined. Curcumin and its analogue
C-150 and bortezomib significantly decreased the cell viability of HL-60 human leukemia cells in a dose-dependent manner. C-150 exhibited
dose-dependent effect onHL60 cells in submicromolar concentrations and was effective at 27 times lower concentration than curcumin. Both
curcumin and its analogue exhibited additive effects with bortezomib (bold data with significant values) (𝑃
1
: bortezomib versus combination;
𝑃
2
: curcumin or C-150 versus combination; two-tailed Student’s 𝑡-test).
— BTZ(50 nM)
BTZ
(12.5 nM)
BTZ
(3.125 nM)
BTZ
(0.78 nM)
— 0.35 0.45 1.26 1.34
C (50 𝜇M) 0.34 0.33 0.35 0.39 0.37
C (25 𝜇M) 0.26 0.23 0.31 0.28 0.27
C (10 𝜇M) 0.48 0.28(P1 < 0.05,P2 < 0.01)
0.31
(P1 < 0.05,P2 < 0.01)
0.42 0.60
C (5𝜇M) 1.10 0.33 0.43 1.21 1.26
C-150 (1 𝜇M) 0.25 0.21 0.19(P1 < 0.01,P2 < 0.05)
0.23 0.25
C-150 (0.5 𝜇M) 0.40 0.26(P1,P2 < 0.01)
0.27 0.27(P1 < 0.01,P2 < 0.05)
0.33
C-150 (0.1 𝜇M) 0.94 0.25 0.41 0.83 1.02
C-150 (0.05 𝜇M) 1.16 0.32 0.39 1.13 1.22
Table 2: Cell viability measurements of curcumin (C), C-150, and bortezomib (BTZ) alone and in combination with CellTiter-Glo assay.
Curcumin and its analogue C-150 significantly potentiated the effect of bortezomib (𝑃
1
: bortezomib versus combination; 𝑃
2
: curcumin or
C-150 versus combination; two-tailed Student’s 𝑡-test).
— BTZ(50 nM)
BTZ
(12.5 nM)
BTZ
(3.125 nM)
BTZ
(0.78 nM)
— 0.11 0.16 0.91 0.94
C (50 𝜇M) 0.12 0.11 0.12 0.12 0.11
C (25 𝜇M) 0.17 0.15 0.13 0.13(P1 < 0.01,P2 < 0.05)
0.13
(P1 < 0.01,P2 < 0.05)
C (10 𝜇M) 0.99 0.11 0.15 0.52(P1,P2 < 0.01)
0.87
C (5𝜇M) 1.08 0.11 0.17 0.79 1.05
C-150 (1 𝜇M) 0.09 0.10 0.10(P1 < 0.01,P2 < 0.05)
0.08 0.08
C-150 (0.5 𝜇M) 0.16 0.10 0.10 0.12 0.16
C-150 (0.1 𝜇M) 0.99 0.08(P1 < 0.05,P2 < 0.01)
0.12
(P1 < 0.05,P2 < 0.01)
0.58
(P1,P2 < 0.01)
0.90
C-150 (0.05 𝜇M) 0.93 0.10 0.15 0.69(P1 < 0.01,P2 < 0.05)
1.02
concentrations both in case of curcumin and C-150, which
can be explained by the difference in sensitivity of the two
assays. While MTS assay measures the activity of NAD(P)H-
dependent cellular oxidoreductase enzymes of themitochon-
dria, the CellTiter-Glo assay detects cellular ATP content.
We found that curcumin had a dose-dependent cytotoxic
effect on HL60 cells (MTS IC
50
= 8.21 𝜇M CTG: IC
50
=
16.77 𝜇M). C-150 also exhibited a dose-dependent effect
on HL60 cells but with 27–60-fold higher potency than
curcumin (MTS IC
50
= 0.30 𝜇M, CTG IC
50
= 0.27 𝜇M).
In the combination experiments, bortezomib was used at
nanomolar concentrations and the determined IC
50
value of
bortezomib alone was 6.56 and 6.90 nM in the MTS and the
CTG assays, respectively.
At the highest applied concentrations, both curcumin and
bortezomib alone produced robust cell death, which could
not be further enhanced by the combined treatment. At the
lowest applied concentration, both curcumin and bortezomib
showed no cytotoxic effect neither alone nor in combination.
Interestingly, only the CTG assay detected appreciable and
statistically significant additive effects. Viability dramatically
decreased after combination of 10𝜇Mcurcumin and 3.125 nM
bortezomib, by 47 and 39% compared to curcumin or
bortezomib alone. Similarly, combination of 5𝜇M curcumin
and 3.125 nM bortezomib also decreased viability compared
to either of the compounds alone (see Table 2).
Combination of C-150 and bortezomib also showed addi-
tive effects. Both methods detected a statistically significant
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Table 3: In vitro effect of curcumin and C-150 on NF-𝜅B signaling. Curcumin and its analogue C-150 alone or in coadministration with
bortezomib decreased the activation of NF-𝜅B pathway in a dose-dependent manner. Modest significant additive effect was recorded after
coadministration of C-150 with bortezomib (𝑃
1
: bortezomib versus combination; 𝑃
2
: curcumin or C-150 versus combination; two-tailed
Student’s 𝑡-test).
— BTZ(50 nM)
BTZ
(12.5 nM)
BTZ
(3.125 nM)
BTZ
(0.78 nM)
— 0.36 0.44 0.54 0.94
C (50 𝜇M) 0.19 0.20 0.22 0.28 0.28
C (25 𝜇M) 0.20 0.24 0.31 0.44 0.34
C (10 𝜇M) 0.43 0.32 0.25 0.47 0.54
C (5𝜇M) 1.05 0.54 0.61 0.64 0.94
C-150 (1 𝜇M) 0.58 0.37 0.41 0.44(P1 < 0.01,P2 < 0.05)
0.65
C-150 (0.5 𝜇M) 0.82 0.36 0.50 0.56 0.72
C-150 (0.1 𝜇M) 1.17 0.32(P1 < 0.05,P2 < 0.01)
0.54 0.58 0.79(P1 < 0.05,P2 < 0.01)
C-150 (0.05 𝜇M) 0.99 0.38 0.54 0.49(P1,P2 < 0.01)
0.95
decrease in viability following the combination of 0.1𝜇M of
C-150 and 3.125 nM of bortezomib. Again, more dramatic
changes were detected by the CTG assay than MTS.
In conclusion, cytotoxic effects of curcumin and its
analogue were detected by two cell viability measurements.
Furthermore, we showed that both curcumin and C-150
additively potentiated the effect of bortezomib.
3.2. In Vitro Effects on the NF-𝜅B Pathway. In the same
concentration ranges as in the viability tests, we determined
the effect of curcumin, C-150, and bortezomib on NF-𝜅B
induction inhibition. All three compounds decreased the
activation of NF-𝜅B markedly in a dose-dependent manner.
IC
50
values were 9.6 𝜇M for curcumin, 0.8 𝜇M for C-150, and
2.0 nM for bortezomib. Significant additive effects could not
be recorded for curcumin and bortezomibwhile, in case of C-
150, amodest additive effect was found in some concentration
combinations (Table 3).
Several studies show a critical role for the NF-𝜅B pathway
in multiple myeloma and leukemia pathogenesis as well
[23, 24]. Hideshima et al. found that bortezomib triggers
the canonical pathway of NF-𝜅B and downregulates I𝜅B𝛼
in primary cells from patients with MM. However, they
also found that bortezomib could inhibit the noncanonical
pathway via inhibition of conversion of p100 to p52 and its
nuclear translocation in MM.1S cells [27]. It was also shown
that the main underlying mechanisms of action of curcumin
were probably based on themodulation ofmultiple important
cellular signaling pathways including NF-𝜅B [5, 14]. Here, we
demonstrated that both types of anticancer agents inhibited
NF-𝜅B induction and curcumin and C-150, in concordance
with their additive cytotoxic potential confirmed by our in
vitro studies, which potentiated the effects of bortezomib.
3.3. Apoptosis Detection. Using FACS analysis and annexin
V and PI staining, the percentage of cells in early or late
apoptosis was determined.
Two doses of curcumin (15 and 25 𝜇M) and C-150 (0.3
and 0.6 𝜇M) were applied. Bortezomib was applied at 20 nM
concentration. Both curcumin and C-150 at their higher
concentration induced 100% and 70% programmed cell
death, respectively.No additive effect could be observedwhen
bortezomib was coadministered (Table 4).
At the lower curcumin concentration (15𝜇M), we could
detect a statistically significant additive effect between cur-
cumin and bortezomib (Figure 1(a)). C-150 at 0.3 𝜇M (50
times lower concentration) possessed a similar apoptotic
effect compared to curcumin at 15 𝜇M (Figure 1(b)). Coad-
ministration of bortezomib also showed a significant additive
effect (Figure 1(b)) with 0.3 𝜇MC-150.
From these results, we can conclude that the novel
curcumin analogue induced a similar level of apoptosis at
50-fold lower concentration than curcumin, while retaining
the ability to potentiate the effect of bortezomib. In addition,
we found that both curcumin and C-150 induced apoptosis
and not necrosis, since the only propidium iodide positive
population did not change (data not shown).
3.4. Analysis of Apoptosis and Cell Cycle Related Gene Expres-
sion Affected by Combination Treatments. We have analysed
the effects of curcumin on the expression of apoptosis and cell
cycle related genes using high-throughput QPCR. Figure 2
depicts the hierarchical cluster analysis of the obtained gene
expression patterns. Previous studies highlighted that treat-
ment with curcumin and bortezomib activated JNK signaling
in multiple myeloma cells [33]. In agreement with that, we
observed increased expression of JUN (jun protooncogene),
a target of JNK (MAPK8, mitogen-activated protein kinase
8), following both curcumin and bortezomib treatment, and
this overexpression was enhanced by their combined use.
A negatively regulated target of JNK signaling BCL2 (B-cell
CLL/lymphoma 2) was also affected; it was downregulated by
curcumin and bortezomib and by their combination. Here,
a significant additive effect was also observed. (b), (c), (d),
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Table 4: Summary of FACS analysis. Percentage of cells in early and late stages of apoptosis and total apoptotic cells as determined by
annexin V and PI staining. The curcumin analogue C-150 induced a similar rate of apoptosis at 50-fold lower concentration than curcumin.
Furthermore, it retained the ability to potentiate the effect of bortezomib.
Early apoptotic cells
Annexin V+/PI−
Late apoptotic cells
Annexin V+/PI+ Total apoptotic cells
% +/− % +/− % +/−
Control 4.5 0.5 3.4 0.6 7.9 1.1
BTZ 20 nM 21.4 0.4 16.5 4.2 37.9 4.6
C 15 𝜇M 18.6 0.8 21.9 4.2 40.5 5.0
C 15 𝜇M + BTZ 20 nM 21.3 1.3 29.1 1.6 50.4 2.9
C 25 𝜇M 45.6 5.0 54.1 4.9 99.6 9.9
C 25 𝜇M + BTZ 20 nM 53.3 8.0 46.5 7.9 99.7 15.9
C-150 0.3 𝜇M 23.8 4.1 7.0 2.7 30.8 6.9
C-150 0.3 𝜇M + BTZ 20 nM 25.4 0.1 21.4 4.4 46.9 4.5
C-150 0.6 𝜇M 24.5 1.0 45.9 3.9 70.4 4.9
C-150 0.6 𝜇M + BTZ 20 nM 24.2 2.0 45.7 3.2 69.8 5.3
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Figure 1: Effect of curcumin (C) or C-150 treatments alone or in combination with bortezomib (BTZ) on cell viability. C-150 (0.3𝜇M) could
potentiate the cytotoxic effect of 20 nM bortezomib at 50-fold lower concentration than curcumin (15𝜇M). Data represent total apoptotic
cells (∗𝑃 ≤ 0.05; ∗∗𝑃 ≤ 0.01, two-tailed Student’s 𝑡-test).
(e), (f), and (g) panels of Figure 2 depict representative genes
of the identified clusters. Panel (b) contains genes that were
activated by both curcumin and bortezomib with additive
effects following the combined treatment. Panels (c) and
(d) contain genes that were markedly downregulated: by all
treatments (Panel (c)) or by only the combined treatment
(Panel (d)). Panels (e), (f), and (g) plot those genes that
were upregulated following combined treatment, suggesting
a role in the observed additive effects between curcumin and
bortezomib.
We can conclude that both apoptosis and cell cycle related
genes were differentially expressed by curcumin and by its
combination with bortezomib.
We have also investigated the effects of the novel analogue
C-150 alone and in combination on genes related to apoptosis
and cell cycle. Figure 3 summarizes the results of hierarchical
cluster analysis and highlights representative genes of the
identified gene expression patterns.
In conclusion, C-150 possessed dose-dependent effects
on certain apoptosis and cell cycle related genes which
could be enhanced by coadministration with bortezomib. In
comparison with cotreatment of bortezomib and curcumin
or C-150, similar gene expression changes were detected,
which suggests a similar mechanism of action.
3.5. Common Genes Influenced by Both Curcumin and C-
150. When gene expression values from curcumin and C-
150 treated cells were plotted against each other and their
correlation was investigated, we concluded that genes most
affected by treatment behaved in a similar fashion suggesting
that the related compounds act with similar mechanism
of action (Figure 4). Several cyclins were unaffected by
treatment but two previously described genes CCND1 (cyclin
D1) and CCND2 (cyclin D2) [34] were both downregulated
by curcumin and C-150. BIRC3 (BIRC3 baculoviral IAP
repeat containing 3) and CASP4 (caspase 4, apoptosis-related
cysteine peptidase) expression was also activated by both
compounds agreeing with previous reports [35, 36].
While fewer genes responded to C-150 treatment alone
compared to curcumin alone (with at least 2-fold induction
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Figure 2: Gene expression analysis of curcumin (C) and bortezomib (BTZ) treatment. Curcumin influenced the expression of a wide range
of cell cycle and apoptosis related genes.
or repression), combined treatment of C-150 and bortezomib
affected the same genes with a similar profile as curcumin
and bortezomib together (Figure 4(b)). Similar to viability
measurements with MTS or CTG and FACS analysis, C-150
induced comparable results to curcumin at more than 40
times less concentration (25𝜇M versus 0.6 𝜇M).
3.6. Genes Influenced Differentially by Curcumin and C-150.
It seems that, among the tested members of the tumor
necrosis factor receptor superfamily TNFRSF10A, B and
C were differentially affected by curcumin and C-150. All
three genes were upregulated by curcumin, while C-150
did not alter their expression. GADD45A (growth arrest
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Figure 3: Gene expression analysis of curcumin analogue C-150 and bortezomib treatment. C-150 influenced the expression of a wide range
of cell cycle and apoptosis related genes at 40–80-fold lower concentration compared to curcumin.
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Figure 4: Correlation of gene expression changes following curcumin and C-150 treatment (a). Correlation of gene expression values of the
combined treatments of curcumin + bortezomib and C-150 (0.6 𝜇M) + bortezomib (b). The natural compound curcumin and its synthetic
analogue C-150 affected nearly the same genes in a similar fashion, but curcumin analogue exerted its effect at 40-fold lower concentration.
and DNA-damage-inducible, alpha) was also differentially
affected by curcumin and its analog. This stress response
gene also mediates the activation of the JNK pathway [37],
which also showed difference in the expression of JUN that
was upregulated by curcumin and was not affected by C-
150. These differences may rise from differences of the two
compounds in target affinity or more likely effectiveness of
the applied concentrations. Further studies are needed to
validate these findings.
3.7. In Vivo Effects of Liposome-Formulated C-150 and Borte-
zomib Alone and in Combination. The effective therapy of
acute myelocytic leukemia still remains problematic. Single
treatment of leukemia and similar hematological cancer types
has shown modest improvement. Despite chemotherapy,
nearly half of the patients with myelocytic leukemias will fall
prey to the disease because of thematuration ofmultiresistant
subclones of leukemia cells [38, 39]. Numerous studies aimed
to find effective compounds that are coadministered with
chemotherapeutic agents which can increase efficacy of the
treatment and lower its side effects. Several studies concluded
that the sensitivity of some cancer cells can be increased
by inhibiting several intracellular pathways in parallel which
finally result in apoptosis. From this evidence, it can make
sense to use the conventional chemotherapeutic agents in
combination with other compounds that can sensitize the
target cells.
We found that curcumin and its synthetic analogue C-
150 can improve the effect of bortezomib in vitro. From the
evidence published by Bai and Zhang and from our findings,
curcumin and its analogueC-150 canmodulate and inactivate
the NF-𝜅B pathway which is necessary to cell survival and
activates the JNK pathway an activator of apoptosis [33]. In
order to prove our hypothesis that C-150 could increase the
effect of bortezomib against promyelocytic leukemia in vivo
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Figure 5: Survival of HL-60 xenograft mice treated with C-150
(3mg/kg), bortezomib (0.15mg/kg), or their combination. The
curcumin analogue C-150 and bortezomib alone exhibited antitu-
mor activity in HL-60 xenograft SCID mice, whereas combined
treatment (bortezomib + C-150) developed a greater antitumor
activity compared to single treatments.
also, a study using a rodent model system was performed in
SCIDmice. In our in vivo study, 8mice were used in 4 groups.
We found that 1/8 mice survived in the control group,
while both bortezomib and C-150 treatment alone was effec-
tive; 3/8 survived after 90 days in both groups. When C-150
and bortezomib were administered in combination, 5/8 mice
survived. In addition, we found that this survival ratio did not
change until 120 days, when the experiment was terminated
(Figure 5).
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Consistent with the results obtained in vitro, bortezomib
or liposome formulated C-150 alone exhibited antitumor
activity in HL-60 xenograft SCID mice, whereas combined
bortezomib and C-150 treatment resulted in greater antitu-
mor activity than single treatments. These results suggest
that the combined use of bortezomib and C-150 could be
developed into an effective option in the treatment of AML.
4. Conclusion
The multitarget action of curcumin and its analog, C-150,
showed additive cytotoxic effects with bortezomib. Curcumin
and its analogue induced expression changes in apoptotic and
cell cycle related genes as determined by high-throughput
QPCR. Most of the affected genes showed similar changes
suggesting that the related compounds act through similar
signaling pathways. Differences in tumor necrosis factor
receptor superfamily and GADD45a gene activity profiles
induced by curcumin and C-150 could be explained by
differences in their target affinity or more likely, effectiveness
of the applied concentrations. The enhanced proliferation
inhibition capability of curcumin and C-150 analogue with
bortezomib was confirmed by in vitro as well as in vivo
studies. Pronounced positive effects of the liposomal formu-
lated curcumin analogue on survival of HL60 xenograftmice
would render thismolecule a potent clinical candidate against
leukemia alone or in combination with other antineoplastic
agents.
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